Eloxx Pharmaceuticals Strengthens Balance Sheet with $66 Million Offering, Advances Exaluren Toward Phase 2b in Alport Syndrome
核心洞察
Eloxx Pharmaceuticals (搜索) completed a $66.0 million public offering and uplisted to Nasdaq, ending Q2 2026 with $62.0 million in cash and no outstanding debt.
The company plans to initiate a Phase 2b trial of exaluren in nonsense mutation Alport syndrome (搜索) in Q3 2026, with topline data expected by mid-2027.
The European Commission granted orphan medicinal product designation for exaluren in autosomal dominant polycystic kidney disease (搜索) (ADPKD) in July 2026.
Eloxx Pharmaceuticals (搜索), Inc. reported second quarter 2026 financial results and outlined a clinical development roadmap anchored by its lead candidate exaluren, a small-molecule ribosomal modulator targeting rare kidney diseases driven by nonsense mutations. The Arlington, Massachusetts-based company ended the quarter with $62.0 million in cash and cash equivalents, following a $66.0 million underwritten public offering and uplisting to the Nasdaq Capital Market in June 2026.
"The second quarter was transformational for Eloxx. Our public offering, with gross proceeds of $66.0 million, together with our uplisting to the Nasdaq Capital Market, has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
Exaluren in Nonsense Mutation Alport Syndrome (搜索)
The U.S. Food and Drug Administration cleared Eloxx's Investigational New Drug application for a Phase 2b clinical trial of exaluren in patients with nonsense mutation Alport syndrome (搜索) (NMAS). The company plans to initiate the trial in the third quarter of 2026. Topline data from the initial 16-week placebo-controlled portion of the study are anticipated by mid-2027, with the final readout expected by the end of 2027.
Exaluren has received orphan drug designation from both the FDA and the European Commission for the treatment of Alport syndrome, underscoring the significant unmet need in this rare genetic kidney disorder.
Orphan Designation in ADPKD
In July 2026, the European Commission granted orphan medicinal product designation in the European Union for exaluren for the treatment of autosomal dominant polycystic kidney disease (搜索) (ADPKD). Eloxx plans to initiate a Phase 2 clinical trial of exaluren in nonsense mutation ADPKD in 2027, with topline data anticipated by mid-2028.
Financial Position and Corporate Developments
The company completed an underwritten public offering of 2,975,000 shares of common stock at $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares, yielding gross proceeds of approximately $66.0 million and net proceeds of approximately $58.3 million after deducting underwriting discounts, commissions, and offering expenses. In May 2026, Eloxx effected a one-for-eleven reverse stock split.
Net loss for the second quarter of 2026 was $4.5 million, or $(0.39) per share, compared to $1.9 million, or $(5.45) per share, for the same period in 2025. Research and development expenses rose to $2.8 million from $0.9 million year-over-year, driven primarily by increased clinical trial expenses for the exaluren program. General and administrative expenses increased to $1.6 million from $0.7 million, reflecting higher professional and consulting fees.
Aggarwal emphasized the company's financial footing: "With approximately $62.0 million in cash, no outstanding debt, and a clear clinical development plan, we believe we are well positioned to advance our Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome (搜索) in the third quarter of 2026 and initiate a Phase 2 clinical trial in nonsense mutation ADPKD in 2027."
Board Strengthening and Partnered Program
In May 2026, Eloxx appointed Stephen W. Webster, former CFO of Spark Therapeutics, and Nina Kjellson, General Partner at Canaan Partners, to its board of directors. Separately, Almirall, S.A. continues development of ZKN-013 for rare dermatological diseases associated with nonsense mutations, including recessive dystrophic epidermolysis bullosa (搜索) and junctional epidermolysis bullosa (搜索). Eloxx remains eligible to receive development and sales milestones of up to approximately $470.0 million, plus tiered royalties on future global sales.
The company believes its current cash position will be sufficient to fund operations into mid-2028, covering anticipated data readouts for both the Alport syndrome and ADPKD programs.